RLMD Jumps As Relmada Insider Buying Sparks Bullish Focus

Relmada Therapeutics Inc. (RLMD) stock rose 12.28% following positive clinical trial news and insider buying by CEO and CFO. The company has no revenue but a strong balance sheet with $218M in cash and no debt. Analysts note a nascent uptrend with support at $4.10 and resistance at $5.00-$5.25. The stock is up from $4.09 to $4.57 on strong volume.

Original reporting
Published Sep 12, 2026, 3:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 13, 2026, 8:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
RLMD Jumps As Relmada Insider Buying Sparks Bullish Focus — source image
Decision brief

The 30-second read

$RLMDBullishMed
01

Why it matters

The Form 4 filing provides fresh, material information that can be acted upon immediately, offering a short‑term trading edge.

02

Market read

The insider buying event caused a notable intraday rally, making the story relevant for short‑term traders in the biotech space.

03

What to watch

The stock's high cash runway may already price in future milestones; the move may be a short‑term technical bounce.

Relevance 5/10Novelty 6/10Timing: today

Background

Relmada Therapeutics (RLMD) is a clinical‑stage biotech with no revenue, strong cash position, and a recent insider buying event.

Company-level read

Ticker impact

$RLMDBullishMedium confidence
Context

Insider purchases of 200,000 shares each by the CEO and CFO were disclosed via a Form 4 filing, triggering a 12.3% price jump.

Expected impact

Potential continuation above $4.60 with support at $4.10; watch for break of $5.00 resistance.

Evidence & confidence

Insider buying in a cash‑rich, pre‑revenue biotech often precedes further price appreciation, but the move may be short‑lived without additional catalyst.

Market effects

Highlights continued volatility in small‑cap biotech stocks driven by insider activity.

Limited to U.S. biotech sector; no broader regional effect.

Minimal global impact; primarily a micro‑cap U.S. equity story.

Counterpoint

Insider buying could be a last‑minute sell‑off by insiders before a negative development.

Key entities

  • Relmada Therapeutics Inc.

    Clinical‑stage biotech subject of the article.

  • CEO (Unnamed)

    Insider purchaser of 200,000 shares.

  • CFO (Unnamed)

    Insider purchaser of 200,000 shares.

Related articles

$RLMDMedAI 8/10

Relmada (RLMD) Q3 2026 Earnings Call Transcript

Relmada (RLMD) reported Q3 2026 progress, including IND submissions for NDV-01 and sepranolone by year-end. NDV-01 showed 86% 18-month CR rate in NMIBC, with favorable safety. Phase 3 trials planned. Cash position of $202.1M expected to fund operations through 2029. Net loss was $13.9M, up from $10.1M YoY.

$RLMDHigh

Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update ● NDV-01 CMC program on track to submit the IND by year-end 2026, with initiation of the registrational Phase 3 SPECTRUM program upon IND clearance ● Long-term extension ND

$RLMDMed

Relmada (RLMD) Q2 2026 Earnings Call Transcript

Relmada Therapeutics (RLMD) reported Q2 2026 results and an execution update. Cash was $217.7M at June 30, 2026, funding operations through 2029. Net loss was $12.9M ($0.11/share). Management expects IND filings for NDV-01 and sepranolone by end-2026 and Phase 3 RESCUE enrollment to start after IND clearance.

$RLMDMed

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update ● Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational

$AVGOMed

Google’s 2027 chip plan is bad news for Broadcom

Google plans to reduce its 2027 orders of Broadcom-designed chips by about 1 million units, shifting more to MediaTek. This move, driven by power and supply constraints, has caused Broadcom's stock to fall over 11%. Analysts estimate Broadcom earned $3 billion from Google in 2023, and the reduction could impact its fiscal 2027 revenue growth. Both companies have not yet commented on the report.